Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$26.8M Buy
102,300
+75,000
+275% +$19.2M 0.04% 455
2026
Q2
$6.87M Sell
27,300
-8,200
-23% -$1.76M 0.01% 975
2026
Q1
$7.72M Sell
35,500
-88,800
-71% -$19.7M 0.01% 931
2025
Q4
$28.4M Buy
124,300
+47,000
+61% +$10.7M 0.05% 377
2025
Q3
$17.9M Buy
77,300
+37,200
+93% +$7.58M 0.03% 548
2025
Q2
$7.44M Sell
40,100
-85,000
-68% -$15.8M 0.01% 890
2025
Q1
$26.2M Sell
125,100
-9,800
-7% -$1.91M 0.07% 339
2024
Q4
$24M Buy
134,900
+53,600
+66% +$9.9M 0.06% 364
2024
Q3
$16.1M Buy
81,300
+36,300
+81% +$6.77M 0.04% 529
2024
Q2
$7.72M Buy
45,000
+9,400
+26% +$1.56M 0.02% 824
2024
Q1
$6.48M Sell
35,600
-3,600
-9% -$620K 0.02% 882
2023
Q4
$6.07M Buy
+39,200
New +$5.71M 0.02% 867
2023
Q3
– Sell
-1,100
Closed -$148K – 1896
2023
Q2
$148K Buy
+1,100
New +$161K ﹤0.01% 1851
2023
Q1
– Hold
0
– – – 2040

Other funds holding ABBV

Man Group's ABBV Position: Q3 2026 in Review

Man Group reduced its AbbVie (ABBV) stake by 11% in Q3 2026, selling an estimated $49.4M and leaving 1,511,312 shares worth $395M. The position accounts for 0.58% of the portfolio, ranked #21.

Man Group first reported a position in ABBV in Q1 2018 and has held it in 32 quarters since. The position peaked at $429M in Q2 2026. 4,257 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Man Group held 1,511,312 shares of AbbVie worth $395M as of Q3 2026.
  • Man Group sold 192,704 AbbVie shares in Q3 2026, an estimated $49.4M.
  • AbbVie made up 0.58% of Man Group's portfolio in Q3 2026, its #21 holding.
  • Man Group first reported a position in AbbVie in Q1 2018 and has held it in 32 quarters since.
  • Man Group's AbbVie position peaked at $429M in Q2 2026.
  • 4,257 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Man Group's 13F filing for Q3 2026, filed 16 Nov 2026.